Vytorin detailed information
| Template:Chembox header| Simvastatin and Ezetimibe | |
|---|---|
|
| |
| Other names | Vytorin |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Ezetimibe/simvastatin (IPA: Template:IPA) is a drug combination used for the treatment of dyslipidemia. It is a combination of ezetimibe (best known as Zetia in the United States) and the statin drug simvastatin (best known as Zocor in the U.S.). The combination preparation is marketed by Merck & Co./Schering-Plough Pharmaceuticals (joint venture) under the trade names Vytorin and Inegy.
Ezetimibe works by reducing the amount of cholesterol that the body absorbs from the food ingested.
Simvastatin is an HMG-CoA reductase inhibitor or statin. It works by blocking an enzyme that is necessary for the body to make cholesterol.
Contraindications
Side effects
- Myopathy
- Rhabdomyolysis
- Myalgia
- Pain in extremities, abdomen,
- Angioedema
- Hepatitis
- Eczema
- Fatigue
- Headache
- Influenza, Pharyngitis, sinusitis and upper respiratory tract infection
Interactions
- Cyclosporine
- Danazol
- Protease inhibitors
- Verapamil
- Amiodarone
- Large amounts of niacin (nicotinic acid), grapefruit juice
- Erythromycin, telithromycin, clarithromycin
- Nefadozone